Cyclacel Pharmaceuticals, Inc. (CYCC)

Oncology Corporate Profile

Stock Performance

3.3700
-0.1900

HQ Location

200 Connell Drive #1500
Berkeley Heights, NJ 07922

Company Description

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using cell cycle control and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases

Website: http://www.cyclacel.com/

Brand Generic Indication
Numoisyn™ LiquidNumoisyn Liquid is indicated for the treatment of symptoms of dry mouth. Numoisyn Liquid relieves the symptoms of dry mouth by enhancing swallowing, improving speech mechanics, and lubricating the oral cavity like natural saliva. Numoisyn Liquid may be used to replace natural saliva when salivary glands are damaged or not functioning. The viscosity is similar to that of natural saliva.
Numoisyn™ LozengesNumoisyn Lozenges are indicated for the treatment of xerostomia (dry mouth). Numoisyn Lozenges provide temporary relief of dry mouth due to damaged salivary function. Numoisyn Lozenges are formulated to support the natural protection of teeth provided by saliva so that no damage occurs to teeth with repeated use of the lozenges.
Xclair™ CreamXclair Cream is indicated to manage and relieve the burning, itching, and pain experienced with radiation dermatitis. Xclair Cream may be used to relieve the pain of firstand second-degree burns.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
sapacitabine / CYC682antimetabolite (oral)1st line metastatic Acute Myelogenous Leukemia (AML)III
sapacitabine / CYC682antimetabolite (oral)Myelodysplastic Syndrome (MDS)II
seliciclib / CYC202cyclin-dependent kinase inhibitor (oral)Nasopharyngeal cancerII
sapacitabine / CYC682antimetabolite (oral)Non Small Cell Lung Cancer (NSCLC)II
sapacitabine (+ decitabine) / CYC682antimetabolite (oral)Acute Myelogenous Leukemia (AML)I
sapacitabine (+ seliciclib) / CYC682 (+ CYC202)antimetabolite (oral)/cyclin-dependent kinase inhibitor (oral)Various cancer typesI
CYC065CDK inhibitorVarious cancer typesPreclinical
CYC140PLK inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.cyclacel.com/

Recent News Headlines

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

3/21/2017 11:00 am

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., March 21, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of ...

Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

3/7/2017 12:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., March 07, 2017-- Cyclacel Pharmaceuticals, Inc., today announced the publication of a peer-reviewed journal article featuring the company’ s cyclin dependent kinase 2/ 9 inhibitors. ...

Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia

2/23/2017 11:05 am

[GlobeNewswire] - -Study did not reach statistically significant improvement in the primary endpoint of overall survival-. -Improvement in secondary endpoint of complete remission rate for the experimental arm-. -Conference ...

Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

2/6/2017 12:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., Feb. 06, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...

Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy

12/6/2016 09:01 pm

[GlobeNewswire] - J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia

12/1/2016 03:02 pm

[at noodls] - December 1, 2016 BERKELEY HEIGHTS, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ('Cyclacel' or the 'Company'), a biopharmaceutical company developing ...

Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia

12/1/2016 12:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., Dec. 01, 2016-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...